Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
307 results about "Hcv hepatitis c virus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepatitis is an inflammation of the liver. One type, hepatitis C, is caused by the hepatitis C virus (HCV). It usually spreads through contact with infected blood. It can also spread through sex with an infected person and from mother to baby during childbirth.
Peptides as NS3-serine protease inhibitors of hepatitis C virus
InactiveUS7012066B2Organic active ingredientsDigestive systemSerine Protease InhibitorsHepatitis C virus
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:DENDREON PHARMA INC +1
Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus
InactiveUS6838475B2Reduce frictionReduce wearBiocideOrganic active ingredientsSerine Protease InhibitorsHepacivirus
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
ActiveUS20060046956A1Modulate activityInhibit HCVBiocideDipeptide ingredientsDiseaseHcv hepatitis c virus
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:MERCK SHARP & DOHME LLC
Hepatitis C virus inhibitors
ActiveUS7041698B2Inhibit functioningEffective treatmentBiocideTetrapeptide ingredientsHcv hepatitis c virusPharmaceutical drug
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Owner:BRISTOL MYERS SQUIBB CO
Peptides as NS3-serine protease inhibitors of hepatitis C virus
The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:DENDREON PHARMA LLC +1
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
InactiveUS20050119168A1HCV infectionImprove overall utilizationBiocideAntiviralsDiseaseStructural formula
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: wherein Z′, L′, M′, R1, X and D are defined herein.
Owner:MERCK SHARP & DOHME CORP
Peptides as NS3-serine protease inhibitors of hepatitis C virus
Owner:DENDREON PHARMA LLC +1
Inhibitors of HCV replication
Owner:BRISTOL MYERS SQUIBB CO
Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Inhibitors of hepatitis c virus replication
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and / or viral production in a cell-based system.
Owner:MERCK SHARP & DOHME LLC
Novel inhibitors of hepatitis C virus NS3/NS4a serine protease
InactiveUS20050153900A1Symptoms improvedOrganic active ingredientsBiocideDiseaseSerine Protease Inhibitors
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Hepatitis C virus inhibitors
ActiveUS20050187165A1Inhibit functioningEffective treatmentBiocideDipeptide ingredientsStereochemistryHepatitis virus c
Owner:BRISTOL MYERS SQUIBB CO
Hepatitis C virus inhibitors
ActiveUS20050143316A1Inhibit functioningEffective treatmentBiocideDipeptide ingredientsHcv hepatitis c virusBiochemistry
Owner:BRISTOL MYERS SQUIBB CO
Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
InactiveUS20080279821A1BiocideHydrocarbon active ingredientsSerine Protease InhibitorsProteinase activity
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Compounds as inhibitors of hepatitis C virus NS3 serine protease
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Owner:MERCK SHARP & DOHME LLC
Depeptidized inhibitors of hepatitis C virus NS3 protease
InactiveUS20050164921A1Symptoms improvedModulate activityBiocideAntiviralsDiseaseHcv hepatitis c virus
The present invention discloses novel depeptidized compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
InactiveUS20090005387A1Inhibit serine protease activityInhibitory activityBiocideOrganic chemistrySerine Protease InhibitorsProteinase activity
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Inhibitors of serine proteases
InactiveUS20070179167A1Reduce riskReduce severityBiocidePeptide/protein ingredientsProteinase activitySerine
Owner:VERTEX PHARMA INC
Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
InactiveUS7173057B2Symptoms improvedModulate activityBiocidePeptide/protein ingredientsHcv hepatitis c virusPharmaceutical Substances
Owner:MERCK SHARP & DOHME CORP
Inhibitors of hepatitis C virus replication
ActiveUS8871759B2Organic active ingredientsDipeptide ingredientsHcv hepatitis c virusViral replication
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and / or viral production in a cell-based system.
Owner:MERCK SHARP & DOHME LLC
Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
InactiveUS20090148407A1Improve liver functionAntibacterial agentsOrganic active ingredientsHcv hepatitis c virusLiver fibrosis
The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Owner:INTERMUNE INC +1
Macrocyclic, pyridazinone-containing hepatitis c serine protease inhibitors
The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
Owner:ENANTA PHARM INC
Hepatitis C Virus Inhibitors
This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Owner:BRISTOL MYERS SQUIBB CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com